New pill shows promise for Hard-to-Treat blood cancer
NCT ID NCT07609823
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests lacutoclax, a daily pill that blocks a protein helping cancer cells survive, in 75 adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants take the drug until their disease worsens or side effects become too severe. The main goal is to see how many people's cancer shrinks or disappears.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lacutoclax (a BCL-2 inhibitor drug taken as a daily pill)
What this could lead to
If successful, this could provide a new treatment option for people with CLL/SLL whose cancer has returned or stopped responding to prior therapies.
What could go wrong
This is an early-phase, single-arm study with no placebo group, so results are preliminary. The drug may not work for everyone and could cause side effects like low blood counts or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••